Recent meaningful negative changes in investment behavior have impacted Harvard Bioscience Inc (NASDAQ: HBIO): the stock’s recent price decline challenged its longer term uptrend.
Harvard Bioscience Inc (NASDAQ: HBIO) has recently experienced extremely important negative changes in fundamentals: the stock’s power rating fell below 50, significant quarterly earnings deceleration occurred, the consensus estimate for December, 2024 decreased significantly, and the consensus estimate for December, 2023 decreased significantly.
In light of these highly negative signals we are reviewing our current Overall Rating of F. We would continue to view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, HBIO is expected to continue to be an important Value Builder.
Harvard Bioscience has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Harvard Bioscience has a neutral Power Rating of 43 but a very low Appreciation Score of 14, triggering the Lowest Value Trend Rating.
Recent Price Action
On 12/5/23, Harvard Bioscience Inc (NASDAQ: HBIO) stock increased 1.5%, closing at $4.62. NORMAL trading volume accompanied the advance. The stock has performed in line with the market over the last nine months and has risen 4.1% during the last week.
Be the first to comment